Guggenheim Reiterates Buy Rating on Dianthus Therapeutics (DNTH): Phase 3 "results exceeded our expectations"
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $200.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)The analyst commented, "DNTH ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)